In CheckMate-040, the authors observed that the effectiveness of nivolumab was unrelated to TPS; however, median overall survival (OS) of patients with PD-L1 ≥1% and <1% was 28.1 and 16.6 months, respectively (p = 0.03), in a later analysis exploring the relationship between PD-L1 expression in tumor tissue and OS in the CheckMate-040 study [50,51,52]. This evidence concerns the gene CD274 and neoplasm.